• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Relief Therapeutics Hldg Ag (OP: RLFTF )

    1.315 -0.010 (-0.75%)
    Streaming Delayed Price Updated: 1:20 PM EDT, Jul 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 539
    Open 1.430
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 1.325
    Today's Range 1.315 - 1.430
    52wk Range 1.140 - 4.750
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
    Via ACCESSWIRE
    Relief Therapeutics Announces Executive Changes
    Via ACCESSWIRE

    Performance

    YTD
    -45.88%
    -45.88%
    1 Month
    -6.44%
    -6.44%
    3 Month
    -8.68%
    -8.68%
    6 Month
    -45.88%
    -45.88%
    1 Year
    -57.99%
    -57.99%

    More News

    Read More
    Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
    Via ACCESSWIRE
    Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
    Via ACCESSWIRE
    Relief Therapeutics has Published its Annual Report
    Via ACCESSWIRE
    RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
    Via ACCESSWIRE
    Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
    Via ACCESSWIRE
    Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
    From Eton Pharmaceuticals
    Via GlobeNewswire
    Relief Therapeutics Renews CHF 50 million Share Subscription Facility
    Via ACCESSWIRE
    Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
    Via ACCESSWIRE
    Relief Therapeutics Announces CEO Transition
    Via ACCESSWIRE
    Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
    Via ACCESSWIRE
    Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
    Via ACCESSWIRE
    Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
    Via ACCESSWIRE
    Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory
    Via ACCESSWIRE
    Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
    Via ACCESSWIRE
    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
    Via ACCESSWIRE
    Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
    Via ACCESSWIRE
    Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
    Via ACCESSWIRE
    Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
    Via ACCESSWIRE
    Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    Relief Therapeutics Announces Executive Leadership Team Change
    Via ACCESSWIRE
    Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
    Via ACCESSWIRE
    Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
    Via ACCESSWIRE
    Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.